key: cord-0728569-xsadfm9s
authors: Dalia, Adam A.; Convissar, David; Crowley, Jerome; Raz, Yuval; Funamoto, Masaki; Wiener-Kronish, Jeanine; Shelton, Kenneth
title: The Role of Extracorporeal Membrane Oxygenation in COVID-19
date: 2022-05-10
journal: J Cardiothorac Vasc Anesth
DOI: 10.1053/j.jvca.2022.05.010
sha: 2a351b376c34f246b861e410561534c34ba99ee1
doc_id: 728569
cord_uid: xsadfm9s

An extracorporeal membrane oxygenation program is an important component in the management of COVID-19 patients, but it is imperative to implement a system that is well supported by the institution and staffed with well-trained clinicians to both optimize patient outcomes and to keep providers safe. There are many unknowns related to COVID-19 and one of the most challenging aspects for clinicians is the lack of predictive knowledge as to why some patients fail medical therapy and require advanced support such as extracorporeal membrane oxygenation. These factors can create challenges during a time of resource scarcity and interruptions in the supply chain. In the current environment in which resources are limited and a pandemic ongoing, we need to focus on evidence based best practice for supportive care of patients in refractory respiratory or cardiac failure with COVID-19. As experience is gained, a greater understanding will develop in this cohort of patients regarding need and timing of extracorporeal membrane oxygenation. As this pandemic continues it will be important to compile and analyze multicentered data pertaining to patient specific outcomes to help guide clinicians caring for COVID-19 patients undergoing extracorporeal membrane oxygenation support. In this paper we aim to demonstrate the strategies utilized by a major quaternary care center in the utilization and management of ECMO for COVID-19 patients.

Coronavirus disease , caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a pandemic with over four hundred and fifty million confirmed cases worldwide as of 2022. While the exact number of patients is not known, large studies have demonstrated that almost 40% of patients admitted to the hospital with COVID-19 in 2020 required ICU admission and mechanical ventilation for respiratory failure secondary to acute respiratory distress syndrome (ARDS) 1 . A subset of these patients continue to have refractory respiratory failure despite traditional measures of low-tidal volume ventilation, prone 3 ventilation, neuromuscular blockade 2,3 , and inhaled pulmonary vasodilators 4 . For this subset of COVID-19 patients, venovenous extracorporeal membrane oxygenation may be utilized as a rescue therapy to support pulmonary function long enough to allow for lung recovery. 5, 6 An even smaller subset of admitted COVID-19 patients, approximately 3-4%, have presented with cardiogenic shock. 7 In late 2020 the U.S. Food and Drug Administration (FDA) issued a policy for extracorporeal membrane oxygenation as a rescue therapy during the COVID-19 pandemic. 8 While there is insufficient data to strongly recommend extracorporeal membrane oxygenation support for patients with COVID-19, a brief review of prior viral pandemics and extracorporeal membrane oxygenation suggests that it is at least a reasonable rescue strategy (Table 1) . [9] [10] [11] [12] [13] Previous respiratory viral outbreaks such as the Middle East respiratory syndrome (MERS) coronavirus in 2012 and the influenza A virus subtype hemagglutinin 1 neuraminidase 1 in 2009 were treated with extracorporeal membrane oxygenation (ECMO); ECMO in these settings exhibited promising potential with survival ranging from 65-77%. 14 Extracorporeal membrane oxygenation in the COVID-19 era is different for several reasons including but not limited to: high risk of contagious spread from patient to provider, allocation of dwindling resources, and challenges with appropriate anticoagulation 15 .

According to the 2020 Extracorporeal Life Support Organization guidelines, COVID-19 patients with refractory hypoxia who fail conventional treatment options (standard lung-protective ventilation, optimal positive end expiratory pressure, and prone ventilation) should be considered for venovenous extracorporeal membrane oxygenation. Specifically, if their partial 4 pressure of oxygen to fraction of inspired oxygen ratio is greater than or equal to 150mmHg and pH < 7.20 (from 7.25 in prior guidelines) with partial pressure of carbon dioxide greater than 80mmHg (from 60mmHg in prior guidelines) for greater than 6 hours. 6 Guidelines also recommend the use of venovenous extracorporeal membrane oxygenation if a patient's partial pressure of oxygen to fraction of inspired oxygen ratio is less than 60 mmHg for greater than 6 hours or partial pressure of oxygen to fraction of inspired oxygen ratio is less than 50 mmHg for greater than 3 hours. 6 Indications for venoarterial extracorporeal membrane oxygenation in COVID-19 patients is similar to non-COVID-19 patients; however, there has been increased reports of myocarditis and thromboembolism directly related to COVID-19 leading to cardiovascular collapse requiring venoarterial extracorporeal membrane oxygenation support. 7 Prior to COVID-19 some institutions, including our own, have developed an extracorporeal cardiopulmonary resuscitation (eCPR) program. Yet the use of such support in COVID-19 positive patients is controversial given the high risk of contamination during an aerosol generating procedure such as chest compressions and intubation. Taking into consideration provider safety and long-term outcomes of patients who have cardiac arrest, we do not currently offer eCPR service to COVID-19 patients. A more comprehensive list of contraindications, both relative and absolute are included in Figure 1 .

It is also important to consider that patients with other pathologies that require extracorporeal membrane oxygenation support such as massive pulmonary embolism or myocardial infarction may also be COVID-19 positive. In addition to primary myocarditis from COVID-19, some COVID-19 patients develop right and/or left ventricular dysfunction related to their severe hypoxemia. These patients are managed in several ways: 1) placement of 5 venovenous extracorporeal membrane oxygenation with concurrent inotropic support, 2) placement of venoarterial extracorporeal membrane oxygenation, 3) cannulation with a hybrid circuit [16] [17] [18] such as venoarterial-venovenous extracorporeal membrane oxygenation which allows for full respiratory and cardiac support, 4) palliative care in patients that fail medical therapy and have contraindications to extracorporeal membrane oxygenation support. 19 Ultimately, our institutional extracorporeal membrane oxygenation criteria have been modified in light of the pandemic to best deploy our resources. Precisely, patients age > 60, body mass index > 35, and patients with chronic organ failure like renal or hepatic are excluded from consideration. A complete list of our absolute and relative contraindications for COVID-19 extracorporeal membrane oxygenation candidacy is presented in Figure 1 . 20

Prior to screening a COVID-19 patient for extracorporeal membrane oxygenation candidacy it is important to have continuous communication regarding availability of critical care resources, evolving triage protocols, and the status of existing extracorporeal membrane oxygenation patients. At the ________, this information is available in near real-time based on continuous collaboration with the hospital incident command system, individual intensive care units, and frequently updated disease projections.

Our COVID-19 testing and screening policy has evolved throughout the pandemic as testing becomes more available and more reliable. The current testing strategy, as of 2022, is for all patients presenting for surgery or inpatient admission to be screened for COVID-19 with nasal polymerase chain reaction testing. Patients who are already inpatient are tested once, 6 and if they remain asymptomatic are not subjected to additional testing. If an inpatient requires mechanical ventilation or extracorporeal membrane oxygenation, they will concurrently be tested for COVID- 19 . Once a patient has tested positive, they must have two consecutive negative tests prior to being considered recovered. These criteria are inclusive for all our extracorporeal membrane oxygenation patients.

Swift identification of potential extracorporeal membrane oxygenation candidates is important during this pandemic for several reasons. This goal is achieved by having frequent evaluations of critically ill patients by a core team of extracorporeal membrane oxygenation physicians (at our institution this is made up of a cardiac surgeon, two cardiac anesthesiology intensivists, and a pulmonary/critical care physician) who review potential cases to reach a consensus of extracorporeal membrane oxygenation candidacy. 21, 22 Once identified as a potential candidate, the patient is followed closely for signs of deterioration to facilitate early and safe cannulation. Provider safety is paramount and avoiding an emergent cannulation which could compromise patient and provider safety is to be avoided at all costs.

Unfortunately, the COVID-19 pandemic is forcing many hospitals in America to consider what was previously an unthinkable problem in American medicine: rationing of care.

Extracorporeal membrane oxygenation is a resource intensive intervention; thus, it is important to select candidates with the highest likelihood of recovery as even an experienced center will rapidly run out of capacity. 7 The goal of any extracorporeal membrane oxygenation cannulation is to minimize complications and to be as efficient as possible, this is especially pertinent with COVID-19 patients. To facilitate efficient cannulation, any patient who is an ECMO candidate and has rapidly progressive respiratory failure necessitating prone ventilation has venous sheaths placed in their right internal jugular vein and right common femoral vein prior to being placed in the prone position. Patients in cardiogenic shock have femoral venous and femoral arterial sheaths placed under ultrasound guidance to avoid a difficult cannulation under duress ( Figure   1 ).

In this pandemic there is the additional consideration regarding protection of healthcare staff, conservation of limited equipment, decontamination of non-disposable equipment, and limitations on safe patient transport. At our institution we have elected to perform all cannulations at the bedside with the most experienced physicians, a cardiothoracic/intensive care trained anesthesiologist and a cardiothoracic surgeon; during the COVID-19 pandemic this was often performed by operators with at least 3 years of experience in cannulating.

Ultrasound guidance is used for all vascular access to improve first pass success. Ultrasound views during cannulation focus on guidewire and cannula position. For transesophageal echocardiography this is achieved with a midesophageal bicaval view and for transthoracic echocardiography a subcostal inferior vena cava view is performed. Transesophageal echocardiography is the preferred and routinely used method for bedside cannulation in non-COVID-19 patients at our institution; however, for COVID-19 patients in the interest of removing a potentially aerosol generating procedure only a portable transthoracic ultrasound is used for cannula positioning and venous wire confirmation. To further improve the safety of 8 cannulation, two single lumen venous cannula placement is preferred as opposed to a dual lumen cannula to minimize need for fluoroscopy or transesophageal echocardiography guidance. This cannulation strategy also allows for maximum flow and to minimize recirculation.

The additional advantages of using a portable transthoracic ultrasound compared to a transesophageal echocardiography machine is the smaller footprint at the bedside as well as the ability to thoroughly wipe down and clean the machine leading to less risk of cross contamination ( Figure 2 ). However, utilizing transthoracic echocardiography instead of transesophageal echocardiography can often times be hindered by body habitus or patient positioning leading to inadequate imaging windows. Other imaging modalities such as fluoroscopy can be helpful during cannulation; but all COVID-19 patients are cannulated at the bedside which hinders the ability to use larger equipment like portable fluoroscopy. In the spirit of reducing cross contamination across the hospital, the risk/benefit of using portable fluoroscopy in routine cannulations deems this imaging modality less desirable.

We have also noted, from literature review, and our own experience, that patients will likely require prolonged mechanical support for respiratory failure and near total pulmonary support necessitating high flow rates (flow goal > 60% of cardiac output). 6 In order to reliably achieve this, we are placing cannulas that can reliably flow up to the maximum flow tolerated by the oxygenator. For patients cannulated for venoarterial extracorporeal membrane oxygenation, we are advising concurrent placement of an appropriately sized distal limb reperfusion cannula under ultrasound guidance in order to reduce the likelihood of needing further bedside procedures. 9 

Extracorporeal membrane oxygenation patients present specific challenges for management at all levels of their care. Intensive care teams need to be familiar with the specifics of extracorporeal membrane oxygenation in order to help troubleshoot circuit complications. 23 At our institution every attempt is made to cohort extracorporeal membrane oxygenation patients into intensive care units with prior extracorporeal membrane oxygenation experience as this had led to improved outcomes. 21 In addition, the cardiac intensive care team is available 24 hours a day, 7 days a week for any patient who is in an atypical location. Due to the potential of caring for these patients outside of these units, we have increased the cross training of our nursing staff to increase familiarity with extracorporeal membrane oxygenation patients. This training includes online refresher courses and online guiding documents. Despite these measures, as stated by the Extracorporeal Life Support Organization, training new staff or centers for extracorporeal membrane oxygenation during this pandemic is not ideal.

There are concerns regarding potential dysregulation of coagulation in COVID-19 patients and close management of anticoagulation is essential. 24 Patients can experience disseminated intravascular coagulation with decreases in platelet count and antithrombin with an increase in fibrin degradation products and D-dimer. 25 Increases in inflammatory mediators (interleukin-2, interleukin-6, and tumor necrosis factor) and perturbances in the coagulation cascade has led to upsurges in both thrombotic and hemorrhagic complications. 26 10 Cerebrovascular complications and myocardial ischemia have been seen in young and otherwise healthy COVID-19 infected patients. 26 This is amplified even further for patients on extracorporeal membrane oxygenation as the continuous contact between the circuit and patients' blood leads to further disturbances in the inflammatory and coagulation response; creating difficulties in deciding a proper anticoagulation strategy. 6 (Table 2 ). If heparin induced thrombocytopenia is suspected or heparin cannot be used, then bivalirudin is used or no anticoagulation in VV-ECMO if appropriate.

In the interest of minimizing provider exposure and conserving valuable intensive care unit resources the number of elective surgical procedures has decreased substantially.

However, patients on extracorporeal membrane oxygenation with COIVD-19 will develop conditions necessitating procedural or surgical intervention and will require the expertise of 11 anesthesiologists. It is therefore important that anesthesiologists are familiar with some common issues that develop on extracorporeal membrane oxygenation. 27 Decannulation Patients on venovenous extracorporeal membrane oxygenation for COVID-19 tend to require longer support (20-40 days) compared to non-COVID-19 patients, based on initial reports out of China. 28 Our institutional data, which included stricter patient inclusion criteria, displays a median duration of support of 12 days. 20 Compared to pre-COVID-19 data, patients on venovenous extracorporeal membrane aoxygenation for COVID-19 at our institution are younger, with a median age of 47 years old. 20 The rate of successful decannulation from venovenous extracorporeal membrane oxygenation was 67%. 20 Our existing weaning protocols have not formally changed for COVID-19, as there has always been a desire to liberate patients from mechanical support as expeditiously as possible (Appendix 3). This is a balanced approach as avoidance of a second cannulation is imperative given the increase in mortality associated with additional cannulations. 29

Extracorporeal membrane oxygenation cannulation is not by default an aerosolizing procedure, but due to the urgent nature, the risk of blood exposure and inadvertent ventilator disconnects during positioning, we are currently treating it with a similar respect. Outside of every patient room prior to beginning the cannulation there is a donning and doffing station; 12 this includes all the disposable personal protective equipment required for cannulations as well as hand sanitizer. All providers in the room wear a N95 or higher respirator mask (or powered air purifier for those unable to wear a N95), face shields, and fluid resistant gowns. In addition, the cannulating providers and assisting nurse wear surgical hoods, level 4 fluid resistant gowns, shoe covers, and double layer surgical gloves. The portable ultrasound used for vascular access and transthoracic ultrasound is completely enclosed in a sterile bag outside of the room prior to placement at the patient bedside ( Figure 2) . Before any cannulation a pre-emptive huddle occurs outside the room where all surgical equipment is prepared and reviewed to reduce the need for any additional providers to enter the room; the huddle involves the intensivist, surgeon, nurse, and respiratory therapist. The equipment included and discussed in the huddle are the portable ultrasound, varying sizes of vascular cannula, and vessel repair surgical kit.

There are two sets of nursing staff, one inside the room assisting the cannulation with a second directly outside of the room available to retrieve additional equipment or medications if needed. This reduces the risk of cross contamination and the need to excessively don and doff personal protective equipment. For new staff, or staff not familiar with cannulation protective procedures a donning and doffing video is presented prior to assuming patient care to represent these protocols.

To decrease the risk of transmission throughout the hospital and community, visitors are prohibited from entering the patients' room. Reducing the number of occasions a provider must enter and exit the patients' room is also crucial and as such laboratory work, imaging tests, and additional procedures are timed together. When entering a patient's room all are 13 required to scan the biothreats tracker, which helps with contact tracing if a provider later tests positive for COVID-19.

Along with protection of providers, the protection of non-COVID-19 patients who may require extracorporeal membrane oxygenation during this pandemic is of paramount importance. While limited, there is data to suggest that COVID-19 does not spread through extracorporeal membrane oxygenation circuit membranes; so it is reasonable to use support for non-COVID-19 patients even if the circuit had been used on a COVID-19 positive patient in the past. 30 For added safety and protection for our non-COVID-19 extracorporeal membrane oxygenation patients, they are placed in a different section of the intensive care unit than the COVID-19 patients. The COVID-19 extracorporeal membrane oxygenation patients are preferably housed in negative pressure rooms that contain an anteroom for donning and doffing. Additionally, the non-COVID-19 patients are cared for by a different team than the COVID-19 extracorporeal membrane oxygenation patients.

Although not common, when a circuit or oxygenator requires exchanging this is done by an expert team of respiratory therapists and perfusionists who are well versed in this procedure (Supplemental Appendix 2). For COVID-19 patients, personal protective equipment required by this team is similar to that required when initiating support.

During the decannulation procedure, staff in the room are expected to wear full personal protective equipment as was done during cannulation. Decannulation is usually performed at the bedside for venovenous extracorporeal membrane oxygenation but for venoarterial extracorporeal membrane oxygenation this is often performed in the operating room due to the need for vessel repair. If the decannulation is to occur in the operating room, 14 there is a singular designated operating room used which contains an ante room for donning and doffing.

In search of expedited and efficient care for COVID-19 patients, several extracorporeal medical devices were given expedited emergency use authorization. 31 One device of particular interest to intensivists is a venovenous extracorporeal carbon dioxide removal device. In April 2020, the Hemolung Respiratory Assist System (ALung, United States of America) was issued emergency use authorization for the treatment of COVID-19 patients with respiratory failure. 31 This transvenous extracorporeal system is used with or without mechanical ventilation to reduce a patient's partial pressure of carbon dioxide and pH when they are unable to correct these metabolic disturbances due to COVID-19. Advances in technology such as venovenous extracorporeal carbon dioxide removal will be key in battling this pandemic as well as future pandemics.

An extracorporeal membrane oxygenation program is an important component in the management of COVID-19 patients. It is imperative to implement a system that is well supported and trained, to both optimize patient outcomes and to keep providers safe. There are many unknowns related to COVID-19 and one of the most challenging aspects for clinicians is the lack of predictive knowledge as to why some patients fail medical therapy and require 15 advanced support such as extracorporeal membrane oxygenation. These factors can create challenges during a time of resource scarcity and interruptions in the supply chain.

In this evolving environment we need to focus on evidence based best practice for supportive care of patients in refractory respiratory or cardiac failure. As experience is gained a greater understanding will develop in this cohort of patients regarding need and timing of extracorporeal membrane oxygenation. As this pandemic continues, and new pandemics arise, it will be important to compile and analyze multicentered data pertaining to patient specific outcomes to help guide clinicians caring for COVID-19 patients undergoing extracorporeal membrane oxygenation support. -The PTT is drawn 2 hours post cannulation, followed by q6h draws with titrations until goal PTT or Anti-Xa is reached.

-Two consecutive draws resulting in no change in the heparin infusion result in labs being drawn q12h rather than q6h. Hemorrhagic and Thrombotic PTT/Anti-Xa Adjustments -In instances of circuit thrombosis or patient hemorrhage, the PTT/Anti-Xa goal is adjusted at the discretion of the treating clinician.

Estimating risk of mechanical ventilation and inhospital mortality among adult COVID-19 patients admitted to Mass General Brigham: The VICE and DICE scores

Early Neuromuscular Blockade in the Acute Respiratory Distress Syndrome

Neuromuscular blockers in early acute respiratory distress syndrome

Low-dose inhaled nitric oxide in patients with acute lung injury: a randomized controlled trial

Initial ELSO Guidance Document: ECMO for COVID-19 Patients with Severe Cardiopulmonary Failure

Extracorporeal Life Support Organization COVID-19 Interim Guidelines

Cardiovascular Collapse in COVID-19 Infection: The Role of Veno-Arterial Extracorporeal Membrane Oxygenation (VA-ECMO). CJC Open

Enforcement Policy for Extracorporeal Membrane Oxygenation and Cardiopulmonary Bypass Devices During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency

Extracorporeal membrane oxygenation for severe Middle East respiratory syndrome coronavirus

Predicting mortality risk in patients undergoing venovenous ECMO for ARDS due to influenza A (H1N1) pneumonia: the ECMOnet score

The Italian ECMO network experience during the 2009 influenza A(H1N1) pandemic: preparation for severe respiratory emergency outbreaks

Extracorporeal membrane oxygenation in severe influenza infection with respiratory failure: A systematic review and meta-analysis

Extracorporeal membrane oxygenation (ECMO) in patients with H1N1 influenza infection: a systematic review and meta-analysis including 8 studies and 266 patients receiving ECMO

ECMO use in COVID-19: lessons from past respiratory virus outbreaks-a narrative review

Association Between Availability of ECMO and Mortality in COVID-19 Patients Eligible for ECMO: A Natural Experiment

Hybrid extracorporeal membrane oxygenation

Controlled flow diversion in hybrid venoarterial-venous extracorporeal membrane oxygenation. Interactive cardiovascular and thoracic surgery

The University of Michigan Experience with Veno-Venoarterial Hybrid Mode of Extracorporeal Membrane Oxygenation

Treatment limitations in the era of ECMO. The Lancet Respiratory medicine

Veno-venous Extracorporeal Membrane Oxygenation for Respiratory Failure in COVID-19 Patients: Early Experience From a Major Academic Medical Center in North America

Extracorporeal Membrane Oxygenation Is a Team Sport: Institutional Survival Benefits of a Formalized ECMO Team

Standardized Team-Based Care for Cardiogenic Shock

Complications of extracorporeal membrane oxygenation for treatment of cardiogenic shock and cardiac arrest: a meta-analysis of 1,866 adult patients. The Annals of thoracic surgery

Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19

COVID-19 and its implications for thrombosis and anticoagulation

COVID-19 and ECMO: the interplay between coagulation and inflammation-a narrative review

Troubleshooting adult ECMO

Extracorporeal Membrane Oxygenation for Coronavirus Disease

Outcomes of Venoarterial Extracorporeal Membrane Oxygenation Patients Requiring Multiple Episodes of Support

SARS-CoV-2 Does Not Spread Through ECMO or Dialysis Membranes

COVID-19) Emergency Use Authorizations for Medical Devices

Extracorporeal Membrane Oxygenation Screening Eligibility/Venovenous Extracorporeal Membrane Oxygenation Cannulation Workflow. Pa02; Partial pressure of oxygen, FiO2; fraction of inspired oxygen, PaCO2; Partial pressure of carbon dioxide

Figure 2: Portable ultrasound used for COVID-19 extracorporeal Membrane Oxygenation cannulation Absolute Contraindications • Age >60 • Body Mass Index > 35 • Absolute Neutrophil Count <1000

Extracorporeal cardiopulmonary resuscitation • Acute organ failure aside from cardiopulmonary and renal failure • Chronic cardiac, pulmonary, renal, or hepatic disease documented on prior hospitalizations or visits

Cannulation Logistics • Cannulation to occur at ICU bedside • Femoral vein and internal jugular cannulation only (reduced need for guided imaging) • Introducer sheaths placed in advance of acute deterioration Pandemic Resource Utilization • Daily assessment by ICU and extracorporeal membrane oxygenation teams regarding need for continued support • Resource allocation will be guided by Hospital Incidence Command System